Does enclomiphene (clomiphene) lower Insulin-like Growth Factor-1 (IGF-1) levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Enclomiphene Can Lower IGF-1 Levels

Yes, enclomiphene (clomiphene) can significantly lower Insulin-like Growth Factor-1 (IGF-1) levels in patients taking it for hypogonadism. The most recent research evidence demonstrates this effect clearly.

Evidence for IGF-1 Reduction

Research from the Journal of the Endocrine Society (2025) found that:

  • 75% of hypogonadal men treated with clomiphene exhibited a decrease in serum IGF-1 levels 1
  • 10% of patients experienced a clinically significant decrease in IGF-1 (>2 standard deviations below age- and sex-matched mean values) 1
  • This reduction was statistically significant (P < .01) 1

Earlier research from 2013 also confirmed that:

  • Both transdermal testosterone and enclomiphene citrate decreased IGF-1 levels (p<0.05) 2
  • The suppression of IGF-1 was greater in the enclomiphene citrate groups compared to testosterone gel 2

Mechanism of Action

The mechanism behind this effect appears to be related to enclomiphene's action as a selective estrogen receptor modulator (SERM):

  1. Enclomiphene stimulates pituitary-derived gonadotropins to generate sex steroids including estrogen 1
  2. Estrogen activates SOCS-3, which can inhibit growth hormone-directed JAK/STAT signaling 1
  3. This inhibition leads to reduced serum IGF-1 levels 1

Clinical Implications

This IGF-1 lowering effect has several important clinical implications:

  • Potential for clinically significant reductions in IGF-1 that could impact health outcomes
  • Need for monitoring IGF-1 levels in patients on enclomiphene therapy
  • Possible symptoms of growth hormone deficiency in some patients

Monitoring Recommendations

Based on the evidence, patients on enclomiphene therapy should have:

  • Baseline IGF-1 measurement before starting therapy
  • Interval monitoring of serum IGF-1 levels during treatment 1
  • Assessment for symptoms of growth hormone deficiency 1
  • Consideration of IGF-1 levels when evaluating overall treatment efficacy

Comparison to Other Treatments

While both testosterone gel and enclomiphene lower IGF-1, research shows:

  • Enclomiphene causes greater suppression of IGF-1 than testosterone gel 2
  • Enclomiphene increases LH and FSH, while testosterone suppresses these hormones 2
  • Enclomiphene maintains or improves sperm counts, unlike testosterone 3

Conclusion

The evidence clearly demonstrates that enclomiphene therapy can lower IGF-1 levels, with some patients experiencing clinically significant reductions. This effect should be considered when prescribing enclomiphene, particularly for patients who may already have borderline low IGF-1 levels or symptoms of growth hormone deficiency.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.